Patents Assigned to Pfizer Inc.
  • TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
    Publication number: 20230002386
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Application
    Filed: August 12, 2022
    Publication date: January 5, 2023
    Applicant: PFIZER INC.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
    Patent number: 11541058
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 3, 2023
    Assignee: PFIZER INC.
    Inventors: James Joseph Hussey, Andrew Gilbert Bright
  • BCKDK inhibitors
    Patent number: 11542270
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • Nitrile-containing antiviral compounds
    Patent number: 11541034
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20220401424
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 22, 2022
    Applicant: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • EZH2 inhibitor combination therapies
    Patent number: 11529344
    Abstract: This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: December 20, 2022
    Assignee: Pfizer Inc.
    Inventors: Manfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
  • Piperazine azaspiro derivatives
    Patent number: 11524954
    Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: December 13, 2022
    Assignee: Pfizer Inc.
    Inventors: Lei Zhang, Erik Alphie LaChapelle, Christopher Ryan Butler, Natasha Mariam Kablaoui, Michael Aaron Brodney, Laura Ann McAllister, Qingyi Yang, Christopher John Helal, Damien Webb
  • Antibodies specific for GUCY2c and uses thereof
    Patent number: 11525010
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: December 13, 2022
    Assignee: PFIZER INC.
    Inventors: Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland LaVallie
  • TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF
    Publication number: 20220390463
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Application
    Filed: July 28, 2022
    Publication date: December 8, 2022
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert ARCH, Jun ZHANG, Michelle MADER, Tetsuya ISHINO, Joel BARD, William FINLAY, Orla CUNNINGHAM, Ciara REILLY, Peter BRAMS, Brigitte DEVAUX, Haichun HUANG, Karla HENNING
  • COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES
    Publication number: 20220387402
    Abstract: In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.
    Type: Application
    Filed: May 15, 2020
    Publication date: December 8, 2022
    Applicant: Pfizer Inc.
    Inventors: Gary E. Aspnes, Scott W. Bagley, John M. Curto, Matthew Dowling, David James Edmonds, Dilinie Fernando, Mark E. Flanagan, Kentaro Futatsugi, David Andrew Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Shawn M. LaCasse, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David Walter Piotrowski, Roger B. Ruggeri, Kristin Wiglesworth
  • STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF
    Publication number: 20220378897
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicant: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • 1-(((2S,3S,4S)-3-ETHYL-4-FLUORO-5-OXOPYRROLIDIN-2-YL)METHOXY)-7-METHOXYISOQUINOLINE-6-CARBOXAMIDE COMBINATIONS AND ORAL DOSAGE FORMS
    Publication number: 20220378707
    Abstract: The present invention is related to the discovery of new oral dosage formulations and combination therapies for 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, for treating conditions ameliorated by inhibition of IRAK4.
    Type: Application
    Filed: November 11, 2020
    Publication date: December 1, 2022
    Applicant: Pfizer Inc.
    Inventors: Allan Joseph Hutchins, Bruce Clinton MacDonald, Vikram Rama Rao, Degui Tang, Weili Yu
  • GLP-1 receptor agonists and uses thereof
    Patent number: 11512070
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: November 29, 2022
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Combination Treatments Of Cancer Comprising A TLR Agonist
    Publication number: 20220370606
    Abstract: The present disclosure describes combination therapies and uses thereof for the treatment of cancer. The combinations therapies include at least a first therapeutic agent and a second therapeutic agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 24, 2022
    Applicant: Pfizer Inc.
    Inventors: Shih-Hsun CHEN, Luca MICCI, Cecilia Marianne ODERUP, Shahram SALEK-ARDAKANI, Jie WEI
  • 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
    Publication number: 20220363673
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: June 24, 2020
    Publication date: November 17, 2022
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Christopher Ryan Butler, Kevin James Filipski, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Kiyoyuki Omoto, Brian Raymer, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • Benzisoxazole sulfonamide derivatives
    Patent number: 11492346
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: November 8, 2022
    Assignees: Pfizer Inc., CTXT PTY LTD
    Inventors: Ylva Elisabet Bergman Bozikis, Michelle Ang Camerino, Pei-Pei Kung, Paul Anthony Stupple, Scott Channing Sutton
  • Chemical Compounds
    Publication number: 20220348555
    Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).
    Type: Application
    Filed: April 12, 2021
    Publication date: November 3, 2022
    Applicant: Pfizer Inc.
    Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
  • Tricyclic compounds and their use as phosphodiesterase inhibitors
    Patent number: 11472805
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 18, 2022
    Assignee: PFIZER, INC.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • Pyrazolo[1,5-a]pyrazin-4-yl derivatives
    Patent number: 11472809
    Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Alpay Dermenci, Andrew Fensome, Brian Stephen Gerstenberger, Matthew Merrill Hayward, Dafydd Rhys Owen, Stephen Wayne Wright, Li Huang Xing, Xiaojing Yang
  • composition and methods thereof
    Patent number: 11472850
    Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen